Skip to content

Cerus CERS Restricted Cash

Restricted Cash at other companies

CorMedix logo
CorMedixCRMD
$656K
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$288K+28.0%
Paysign logo
PaysignPAYS
$179.5M+61.0%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Reported directly by Cerus in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsNoncurrent.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's restricted cash?
Cerus (CERS) reported restricted cash of $631K in Q1 2026.
How has Cerus's restricted cash changed year-over-year?
Cerus's restricted cash decreased by 43.1% year-over-year, from $1.11M to $631K.
What is the long-term trend for Cerus's restricted cash?
Over 5 years (2020 to 2025), Cerus's restricted cash has grown at a -22.7% compound annual growth rate (CAGR), from $2.31M to $639K.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.